Trastuzumab (Herceptin) for Early-Stage Breast Cancer

Hematology/Oncology Clinics of North America

Volumn 21, Issue 2, 2007, Pages 239-256

  Ismael, Gustavo ^a   Rosa, Daniela Dornelles ^a   de Azambuja, Evandro ^a   Braga, Sofia ^a   Piccart Gebhart, Martine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; ADVERSE OUTCOME; BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; EARLY CANCER; FINLAND; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTERSTITIAL PNEUMONIA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 34249048896     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.03.003     Document Type: Review

References (34)

1. American Society of Cancer. Available at: www.cancer.org. Accessed April 12, 2007.
2. Peto R., Boreham J., Clarke M., et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355 (2000) 1822
3. Chia S., Speers C., Kang A., et al. The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort. [abstract 22]. Proc Am Soc Clin Oncol 22 (2003) 6
4. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
5. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
6. Pegram M., and Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 27 5 Suppl 9 (2000) 13-19
7. Ravdin P.M., and Chamness G.C. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review. Gene 159 (1995) 19-27
8. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
9. Baselga J., Carbonell X., Castañeda-Soto N.J., et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23 (2005) 2162-2171
10. Slamon D.J., Leyland-Jones B., Shak S., et al. Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer. A phase III, multinational, randomized controlled trial. N Engl J Med 344 (2001) 783-792
11. Burstein H.J., Kurten I., Campos S.M., et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19 10 (2001) 2722-2730
12. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 23 (2005) 4265-4274
13. Bell R. What can we learn from Herceptin trials in metastatic breast cancer?. Oncology 63 Suppl 1 (2002) 39-46
14. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
15. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
16. Kim C., Bryant J., Home Z., et al. Trastuzumab sensitivity of breast cancer with coamplification of HER2 and cMYC suggests pro-apoptopic function of dysregulated cMYC in vivo [abstract 46]. Breast Cancer Res Treat 94 Suppl 1 (2006) S6
17. Slamon D., Eiermann W., Robert N., et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients. Breast Cancer Res Treat 100 (2006) abstract 25
18. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
19. Smith I., Procter M., Gelber R., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 9555 (2007) 29-36
20. Bendell J.C., Domchek S.M., Burstein H.J., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97 (2003) 2972-2977
21. Seidman A., Hudis C., Pierri M., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20 5 (2002) 1215-1221
22. Perez E.A., and Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22 2 (2004) 322-329
23. Pugatsch T., Abedat S., Lotan C., et al. Anti-ErbB2 treatment induces cardiotoxicity by interfering with cell survival pathways. Breast Cancer Res 8 (2006) R35
24. Chien K.R. Herceptin and the heart-a molecular modifier of cardiac failure. N Engl J Med 354 (2006) 789-790
25. Ozcelik C., Erdmann B., Pilz B., et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 99 13 (2002) 8880-8885
26. Ewer M., and Lippman S. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23 13 (2005) 2900-2902
27. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23 31 (2005) 7811-7819
28. Gopalakrishnan S., and Linnane J. The other side of the coin. BMJ 331 (2005) 1202-1203
29. Littlejohns P. Trastuzumab for early breast cancer: evolution or revolution?. Lancet Oncol 7 1 (2006) 22-23
30. Neyt M., Albrecht J., and Cocquyt V. An economic evaluation of Herceptin® in adjuvant setting: the Breast Cancer International Research Group 006 trial. Ann Oncol 17 3 (2006) 381-390
31. Garrison L.P., Perez E.A., Dueck A., et al. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+ breast cancer. J Clin Oncol 24 18S (2006) 306s
32. Ismael G. Access to trastuzumab in the adjuvant treatment of patients with HER-2 positive breast cancer: the challenges of applying the benefits. Breast International Group Newsletter 8 (2006) 7-10
33. Joensuu H., Isola J., Lundin M., et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 9 (2003) 923-930
34. Hanrahan E.O., Valero V., Gonzalez-Angulo A.M., et al. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0). J Clin Oncol 24 13 (2006) 2113-2122